Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 12/20 | 0.46 |
| ▸ | CDK2 | P24941 | 12/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 12/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628285 | 0.78 | SMN1; SMN2 (0.44) | CCNE1CDK2CDK5SMN1; SMN2OGA | |
| SCHEMBL13148690 | 0.76 | CCNE1 (0.35) | CCNE1CDK2CDK5SMN1; SMN2CDK5R1 | |
| SCHEMBL765631 | 0.73 | SMN1; SMN2 (0.43) | CCNE1CDK2CDK5SMN1; SMN2OGA | |
| SCHEMBL32672066 | 0.71 | CCNE1 (0.61) | CCNE1CDK2CDK5SMN1; SMN2OGA | |
| SCHEMBL628009 | 0.71 | ESR2 (0.41) | CCNE1CDK2CDK5SMN1; SMN2HTT | |
| SCHEMBL20883053 | 0.71 | CCNE1 (0.60) | CCNE1CDK2CDK5SMN1; SMN2OGA | |
| SCHEMBL15943684 | 0.71 | RAB9A (0.57) | SMN1; SMN2 | |
| SCHEMBL5780845 | 0.69 | CCNE1 (0.65) | CCNE1CDK2CDK5SMN1; SMN2CDK5R1 | |
| SCHEMBL4479801 | 0.69 | SMN1; SMN2 (0.56) | CCNE1CDK2CDK5SMN1; SMN2MAPK1 | |
| SCHEMBL20522416 | 0.69 | CCNE1 (0.48) | CCNE1CDK2CDK5SMN1; SMN2CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| EP-2419417-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | CCNE1 885/4885CDK2 760/4885CDK5 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.